Synergizing Radiation Therapy and Immunotherapy for Curing Incurable Cancers. Opportunities and Challenges
Overview
Affiliations
The combination of radiation therapy and immunotherapy holds particular promise as a strategy for cancer therapeutics. Evidence suggests that immunotherapy is most beneficial alone when employed early in the disease process or in combination with standard therapies (eg, radiation) later in the disease process. Indeed, radiation may act synergistically with immunotherapy to enhance immune responses, inhibit immunosuppression, and/or alter the phenotype of tumor cells, thus rendering them more susceptible to immune-mediated killing. As monotherapies, both immunotherapy and radiation may be insufficient to eliminate tumor masses. However, following immunization with a cancer vaccine, the destruction of even a small percentage of tumor cells by radiation could result in crosspriming and presentation of tumor antigens to the immune system, thereby potentiating antitumor responses. Learning how to exploit radiation-induced changes to tumor-cell antigens, and how to induce effective immune responses to these cumulatively immunogenic stimuli, is an exciting frontier in cancer therapy research. This review examines mechanisms by which many forms of radiation therapy can induce or augment antitumor immune responses as well as preclinical systems demonstrating that immunotherapy can be effectively combined with radiation therapy. Finally, we review current clinical trials where standard-of-care radiation therapy is being combined with immunotherapy.
The Tight Relationship Between the Tumoral Microenvironment and Radium-223.
Conte M, Tomaciello M, De Feo M, Frantellizzi V, Marampon F, De Cristofaro F Biomedicines. 2025; 13(2).
PMID: 40002869 PMC: 11853176. DOI: 10.3390/biomedicines13020456.
Cheng C, Chang J, Ho A, Sie Z, Peng C, Wang C Cancer Immunol Immunother. 2024; 73(9):175.
PMID: 38953994 PMC: 11219622. DOI: 10.1007/s00262-024-03761-y.
Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma.
Oshima K, Tsushima T, Ito Y, Kato K Jpn J Clin Oncol. 2024; 54(4):395-402.
PMID: 38342589 PMC: 10999767. DOI: 10.1093/jjco/hyae005.
Abdelhakm L, Kandil E, Mansour S, El-Sonbaty S Biol Trace Elem Res. 2023; 201(11):5278-5297.
PMID: 36905557 PMC: 10509080. DOI: 10.1007/s12011-023-03596-1.
Wang C, Ho A, Chang C, Sie Z, Peng C, Chang J Cancer Immunol Immunother. 2023; 72(6):1865-1880.
PMID: 36688994 PMC: 10198930. DOI: 10.1007/s00262-023-03379-6.